Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR

Naoki Takezako, Hirohiko Shibayama, Hiroshi Handa, Shotaro Hagiwara, Shuji Ozaki, Kenshi Suzuki, Hiroshi Kosugi, Masaki Ri, Isamu Sugiura, Ilseung Choi, Toshihiro Miyamoto, Shinsuke Iida

研究成果: Contribution to journalArticle査読

フィンガープリント

「Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

Medicine & Life Sciences